PDF
(Download)
|
- Ashwagandha (Withania somnifera, Solanaceae)
- Sexual Function
- Female Sexual Dysfunction
|
Date:
10-14-2016 | HC# 031662-554
|
Re: Ashwagandha Improves Sexual Function in Premenopausal Women
Dongre
S, Langade D, Bhattacharyya S. Efficacy and safety of ashwagandha (Withania somnifera) root extract in
improving sexual function in women: a pilot study. Biomed Res Int. October 4, 2015;2015:284154. doi: 10.1155/2015/284154.
Many factors can lead to a lack of sexual
function and desire in women, including stress or physical problems. Botanicals
may be useful to alleviate these. Ashwagandha (Withania somnifera, Solanaceae) is used as an adaptogen, and the
root extract has been shown to be efficacious in treating sexual problems. This
randomized, double-blind, placebo-controlled study investigated whether a
high-concentration ashwagandha root water extract (HCARE) (KSM-66®;
Ixoreal Biomed; Los Angeles, California) would alleviate stress or modulate
hormones to affect female sexual dysfunction (FSD).
This study took place in India and enrolled women
diagnosed with FSD and meeting criteria for hypoactive sexual desire disorder
(HSDD), female sexual arousal disorder (FSAD), female orgasmic disorder (FOD),
or "combined genital and subjective arousal disorder." Patients enrolled
scored <26 on the Female Sexual Function Index (FSFI, an index of function
items, where an elevated score is indicative of better sexual function) and
>11 on the Female Sexual Distress Scale (FSDS, a scale addressing worry and
distress about sex, where a lower score shows lower distress). Patients were
21-50 years old, in a heterosexual partnership for a year or more, and had a
history of sexual activity. Additional inclusion criteria were the agreement to
have sex twice per week with attempts at orgasm, the use of condoms, and ability
to speak, read, and write fluent English. Those who had underlying untreated
endocrine disease; had experienced painful sex within the past year; appeared
to be experiencing sexual distress or exploitation; were pregnant, lactating,
infertile, or in menopause; suffered from psychiatric conditions or drug abuse;
used hormonal contraceptives or had taken other drugs or supplements for sexual
function within the past year; or had an allergy to ashwagandha were excluded.
In total, 50 patients were enrolled, with 25 each
randomly assigned to the treatment and placebo groups. The HCARE product used
was selected for its high content of >5% withanolides, which was confirmed
by high-performance liquid chromatography (HPLC). For placebo, starch was used.
Treatment and placebo were placed in capsules of 300 mg each, with 2 doses of 1
capsule taken per day (after meals with water) for 8 weeks. Along with the
treatment or placebo, patients underwent counseling to address FSD.
The primary outcome was the FSFI score, which
measures aspects of sexuality such as desire, arousal, lubrication, pain,
orgasm, and satisfaction. Secondary outcomes included the FSDS, the Sexual
Activity Record (SAR, a gauge of the frequency of sex), the Patients' Global
Assessment of Response to Therapy (PGART, a 5-point scale rating sexual
activity and satisfaction), and the Patients' Global Assessment of Tolerability
to Therapy (PGATT, an assessment of adverse side effects on a 5-point scale). Assessments
were conducted at baseline and 4 and 8 weeks. Returned capsules were used to
gauge compliance, with ≥80% consumption considered to be compliant.
Patients' mean age was 28.12 ± 5.12 in the
treatment group and 29.44 ± 6.14 in the placebo group. It is mentioned that the
enrollment criteria and study demands resulted in a homogeneous patient
population consisting mostly of highly stressed, married, affluent stay-at-home
mothers. No patients dropped out or were excluded after enrollment. At
baseline, patients' FSFI scores were within the range associated with FSD. At
weeks 4 and 8, total FSFI scores for the treatment group had improved
significantly more than in the placebo group (P<0.001). At 8 weeks, the FSFI
score was significantly greater in the HCARE group as compared with the placebo
group (23.86 vs. 20.06, P<0.001), compared to values at week 0 of 13.63 vs.
13.57. The treatment group had significantly greater improvements in the arousal,
lubrication, orgasm, and satisfaction domains of the FSFI (at 8 weeks, P<0.001
for all comparisons). The "desire" domain did not improve more in the
treatment group; the authors note that this means it would be inappropriate to
describe HCARE as an "aphrodisiac."
Additionally, FSDS scores in those taking HCARE
decreased significantly more (indicating improvement) as compared to the
placebo group at both 4 and 8 weeks (P<0.001 for both). No significant differences
were seen in overall SAR scores, though at 8 weeks the number of
"successful" sexual encounters was greater in the treatment group
(P<0.001). On the 5-point PGART scale, 15 in the treatment group rated the
response as "excellent," 9 as "good," and 1 as
"moderate." [Note: The authors failed to provide comparable data for
the placebo group.] For those taking HCARE, no adverse effects were observed,
and compliance was considered "excellent" for both groups.
This study suggests the efficacy of ashwagandha
water extract in treating FSD. Suggested mechanisms may include ashwagandha's
previously reported antistress bioactivity, as well as modulating hormones such
as testosterone. The authors mention that cultural attitudes about sex may have
affected the survey scores and note that significant, though lesser,
improvements in the placebo group may reflect efficacy of counseling. A
discussed limitation is the small sample size, and further research would be necessary
to determine the mechanism of action behind the observed results. The
diagnostic labels applied in this study have been the subject of some
controversy.
Ixoreal Biomed provided the study product and some
financial assistance for this study.
—Amy C. Keller, PhD
|